At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Prazosin Hydrochloridedrug
Likely dose
Prazosin Hydrochloride 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploring the Effects of Prazosin on Basal Dopamine in Healthy Humans: A [11C]-(+)-PHNO PET Pilot Study
In Brief
A Phase 1 clinical trial evaluating Prazosin Hydrochloride for Healthy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to find out whether short term treatment with a antihypertensive medication prazosin, can influence the levels of a dopamine in the brain. We will examine the levels of dopamine in the the brain using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI). We hypothesize that there will be no significant changes in dopamine levels in healthy individuals taking prazosin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsOntario Lung Association, Pfizer
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedDec 2013
Primary CompletionAug 2016
TodayJul 2026
First PostedDec 3, 2013
Enrollment StartNov 1, 2013
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.6 years ago
Interventions
Prazosin Hydrochloridedrug
Gradual upward titration to 15mg/day for approximately three weeks.